Rapamycin Interactions: Alcohol, Caffeine, Food and Other Compounds

What the Rapamycin Interaction Literature Actually Covers

Questions about combining rapamycin with alcohol, caffeine, meals or other drugs are common, but the published record answers them unevenly. The bulk of it consists of deliberate drug–drug combination experiments in animals, cells and defined patient populations — for example the additive combination of trametinib and rapamycin that researchers reported extended mouse healthspan and lifespan in a 2025 Nature Aging paper (PMID 40437307). Lifestyle substances such as ethanol and caffeine appear in the mTOR literature on their own terms, not as co-administration studies alongside rapamycin.

This page separates three categories: (1) combinations that were directly tested and reported, (2) substances where only parallel mechanistic literature exists, and (3) questions with no study in the verified set at all. Where a claim rests on mechanism rather than measurement, it is explicitly labelled as mechanistic reasoning. This page is for educational purposes only and is not medical advice; consult a licensed physician about anything relating to health, medication or drug combinations.

Rapamycin and rapalogs are not treated as one compound

Interaction papers frequently use sirolimus, everolimus or temsirolimus interchangeably in casual summaries, but a 2023 Gerontology article argued that rapamycin should not be grouped with rapalogs and examined the pharmacological grounds for keeping the categories distinct (PMID 36617414). That distinction matters when reading combination research, because findings generated with one agent were not automatically transferable to another in the framing that paper set out (PMID 36617414).

Rapamycin and Alcohol: What the Literature Examined

No study in the verified set administered rapamycin and alcohol together to human volunteers to measure an interaction. What exists instead are three separate lines of work that intersect at the mTOR and autophagy pathways.

First, ethanol metabolism itself was studied as an autophagy trigger: a 2021 Redox Biology paper investigated hydrogen-peroxide-mediated autophagy during ethanol metabolism and identified H₂O₂ generated during that metabolism as a mediator of the autophagic response (PMID 34343907). Because rapamycin is characterised throughout the ageing literature as an mTOR inhibitor and autophagy inducer, researchers commonly reason that two autophagy-modulating inputs could converge — that is mechanistic reasoning drawn from the pathway map, not an interaction measured in the study described above (PMID 34343907).

Second, the role of mTOR in alcohol-related organ injury was reviewed directly. A 2022 article in Liver Research examined liver–adipose tissue crosstalk in alcohol-associated liver disease and the role mTOR signalling plays in that crosstalk (PMID 37124481). The review situated mTOR as a node in alcohol-associated metabolic injury rather than reporting a rapamycin–alcohol dosing interaction (PMID 37124481).

Third, rapamycin was tested in an alcohol-injury model rather than against a drink. A 2017 study in Experimental and Therapeutic Medicine reported therapeutic effects of rapamycin in an experimental model of alcoholic cardiomyopathy (PMID 28966668). That design — intervention applied to alcohol-induced pathology — answers a different question from whether concurrent alcohol intake alters rapamycin exposure or tolerability in a person, which the study did not address (PMID 28966668).

What is missing from the alcohol evidence

• No pharmacokinetic study in the verified set measured rapamycin blood levels with and without ethanol.
• No clinical trial in the verified set randomised participants to alcohol exposure while on rapamycin.
• The available work is either ethanol-only mechanistic research (PMID 34343907) or rapamycin applied to alcohol-induced injury models (PMID 28966668).

Rapamycin and Caffeine: What the Literature Examined

Caffeine enters this discussion because it has been studied as a modifier of the same anabolic signalling axis that rapamycin inhibits. A 2017 paper in Applied Physiology, Nutrition, and Metabolism examined the effect of caffeine on skeletal muscle anabolic signalling and hypertrophy (PMID 28177708). The study's subject was caffeine in muscle tissue; rapamycin co-administration as an interaction variable was not the question that paper set out to answer (PMID 28177708).

Labelled as mechanistic reasoning: researchers who discuss a possible caffeine–rapamycin overlap do so because both are described as acting on or near mTOR-dependent anabolic signalling in muscle, as framed in the caffeine study (PMID 28177708). No measurement of combined exposure, additive signalling suppression, or altered rapamycin pharmacokinetics with caffeine appears in the verified papers on this page. Pathway adjacency is a hypothesis-generating observation, not a reported interaction.

Food, Fasting and Metabolic State

Rapamycin's relationship with feeding state is usually raised in two different senses: whether food changes drug absorption, and whether rapamycin changes metabolic and feeding-related biology. The verified literature reviewed here speaks only to the second.

A 2016 study in The Journals of Gerontology Series A reported that rapamycin normalised serum leptin in aged rats, and that researchers attributed this to both alleviation of obesity and reduced leptin synthesis (PMID 25617379). That finding sits in the metabolic-effects literature: it describes what the compound did to a feeding-related hormone in an animal model, not how a meal altered the compound (PMID 25617379).

Adipose biology appears again in a 2025 Molecular Medicine paper that evaluated candidate preclinical "kill or cure" strategies for MFN2-related lipodystrophy, a disorder of adipose tissue (PMID 40759924). It is a strategy-screening study in a rare metabolic disease model rather than a nutrition or fasting interaction experiment (PMID 40759924).

Stated plainly: no food-effect pharmacokinetic study — high-fat meal versus fasted administration, or timed fasting protocols — appears among the verified papers summarised on this page. Any statement about meal timing and rapamycin absorption would therefore not be supported by the evidence cited here.

Combinations With Other Compounds That Were Directly Studied

This is where the interaction literature is strongest, because the combinations were designed, administered and measured. The table summarises what researchers reported.

Additive versus synergistic language

These two words are not decorative. The 2025 mouse ageing study described the trametinib and rapamycin effect as additive, meaning the combined outcome tracked the sum of the separate contributions in that model (PMID 40437307). By contrast, the 2023 Journal of Zhejiang University Science B study described dichloroacetic acid and rapamycin as acting synergistically against tumour progression, a stronger claim about combined effect exceeding the separate ones (PMID 37190889). Readers comparing combination papers benefit from checking which term the authors used and in which model.

Protective combinations are still combinations

Not every co-exposure study asks whether one drug amplifies another's toxicity. In the 2022 Journal of Reproduction and Development study, rapamycin was examined as a protective agent against damage caused by a second drug, with researchers reporting maintenance of the primordial follicle pool under cyclophosphamide exposure (PMID 35718464). Similarly, the 2021 Frontiers in Pharmacology work paired rapamycin with a low dose of imatinib to study combination therapy in pulmonary hypertension rather than to document an adverse interaction (PMID 34858182).

Adverse Events in Interaction and Combination Research: What Studies Report

Combination and clinical-population studies are also where unexpected adverse findings surface. A 2023 paper in ERJ Open Research reported unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis (PMID 37589458). The finding was described by the authors as unexpected, which illustrates that adverse signals in this field have emerged from observation in specific patient populations rather than from predictions made on pathway grounds (PMID 37589458).

Tolerability considerations also shaped combination design elsewhere: the 2021 Frontiers in Pharmacology study paired rapamycin specifically with a low dose of imatinib when evaluating combination therapy in pulmonary hypertension (PMID 34858182). The 2025 mouse study likewise reported healthspan and lifespan outcomes for the trametinib-plus-rapamycin combination as its endpoints, meaning tolerability in mice was assessed in that experimental context and not in humans (PMID 40437307). Because the alcohol- and caffeine-related papers on this page did not co-administer rapamycin, no adverse-event data for those pairings exist within the cited set (PMID 34343907, PMID 28177708).

How to Read Gaps in an Interaction Literature

Three patterns recur when interaction questions are compared against what was actually measured:

1. Pathway adjacency is not interaction data. Ethanol metabolism was linked to autophagy in a 2021 study without rapamycin being the variable under test (PMID 34343907).
2. Model species and disease context constrain the claim. Leptin normalisation was reported in aged rats (PMID 25617379), while airway hyperreactivity was observed in a human lymphangioleiomyomatosis setting (PMID 37589458).
3. Compound identity matters. Whether a paper used rapamycin or a rapalog was argued to be a substantive distinction rather than nomenclature (PMID 36617414).

Taken together, the verified papers summarised here describe deliberate drug combinations in animals and patient populations — trametinib (PMID 40437307), dichloroacetic acid (PMID 37190889) and imatinib (PMID 34858182) — alongside separate mTOR-pathway work on ethanol (PMID 37124481) and caffeine (PMID 28177708). None of this constitutes guidance, and nothing here should be read as a judgement about whether any combination is appropriate for any individual.

References

• Why Is Rapamycin Not a Rapalog? (Gerontology, 2023)
• Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis (ERJ Open Research, 2023)
• Rapamycin maintains the primordial follicle pool and protects ovarian reserve against cyclophosphamide-induced damage (The Journal of Reproduction and Development, 2022)
• Preclinical evaluation of candidate "kill or cure" strategies to treat MFN2-related lipodystrophy (Molecular Medicine, 2025)
• H2O2-mediated autophagy during ethanol metabolism (Redox Biology, 2021)
• Dichloroacetic acid and rapamycin synergistically inhibit tumor progression (Journal of Zhejiang University Science B, 2023)
• The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan (Nature Aging, 2025)
• Liver-adipose tissue crosstalk in alcohol-associated liver disease: The role of mTOR (Liver Research, 2022)
• Rapamycin Normalizes Serum Leptin by Alleviating Obesity and Reducing Leptin Synthesis in Aged Rats (The Journals of Gerontology Series A, 2016)
• Therapeutic effects of rapamycin on alcoholic cardiomyopathy (Experimental and Therapeutic Medicine, 2017)
• The effect of caffeine on skeletal muscle anabolic signaling and hypertrophy (Applied Physiology, Nutrition, and Metabolism, 2017)
• Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension (Frontiers in Pharmacology, 2021)